Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405932 | 1.00 | BRAF (0.47) | BRAFHTR2CMCHR1KDM1AMAPK14 | |
| SCHEMBL22659083 | 0.92 | HTR2C (0.44) | BRAFHTR2CMCHR1GSK3BDYRK1A | |
| SCHEMBL22659082 | 0.90 | MAPK14 (0.53) | BRAFHTR2CMCHR1KDM1AMAPK14 | |
| SCHEMBL22659007 | 0.90 | BRAF (0.45) | BRAFHTR2CMCHR1KDM1AMAPK14 | |
| SCHEMBL22659336 | 0.86 | HTR2C (0.44) | BRAFHTR2CMCHR1GSK3BDYRK1A | |
| SCHEMBL29403296 | 0.86 | BRAF (0.46) | BRAFKDM1AMAPK14GRIN2B | |
| SCHEMBL22659199 | 0.86 | BRAF (0.46) | BRAFKDM1AMAPK14GRIN2B | |
| SCHEMBL22659115 | 0.84 | ESR2 (0.45) | BRAFMAPK14GSK3BDYRK1AWNT1 | |
| SCHEMBL24571213 | 0.83 | NTRK1 (0.47) | BRAFHTR2CMCHR1MAPK14 | |
| SCHEMBL29406420 | 0.83 | NTRK1 (0.47) | BRAFHTR2CMCHR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | BRAF 1104/4885HTR2C 676/4885MCHR1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.